Skip to main content
Download PDF

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Experimental Hematology & Oncology volume 9, Article number: 26 (2020) Cite this article

Abstract

Background

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substantially improved patients’ prognosis, drug resistance remains one of the major challenges in CML therapy. MicroRNAs (miRNAs), a class of short non-coding RNAs acting as post-transcriptional regulators, are implicated in CML progression and drug resistance. The aim of the present study was to analyze the miRNA expression profiles of 45 treatment-naïve CML patients in chronic phase (28 peripheral blood and 17 bone marrow samples) with respect to future response to imatinib therapy.

Methods

TaqMan low density arrays were used to analyze the miRNA expression pattern of the patient samples. For selected microRNAs, reporter gene assays were performed to study their ability to regulate CML associated target genes.

Results

Significant lower expression levels of miR-142-5p were identified in both, peripheral blood and bone marrow samples of future non-responders suggesting a potential tumor suppressor role of this miRNA. This was supported by reporter gene assays that identified the survival, proliferation and invasion promoting CML related genes ABL2, cKIT, MCL1 and SRI as targets of miR-142-5p and miR-365a-3p, the latter identified as potential biomarker in peripheral blood samples.

Conclusion

MiR-142-5p and to a certain extend also miR-365a-3p were able to discriminate treatment-naïve CML patients not responding to imatinib in the course of their treatment from patients, who responded to therapy. However, further large-scale studies should clarify if the identified miRNAs have the potential as predictive biomarkers for TKI resistance.

Background

Chronic myeloid leukemia (CML) is a clonal haemopoietic stem cell disorder characterized by a reciprocal translocation between the q-arms of chromosomes 9 and 22 thereby generating the BCR-ABL1 fusion gene [1]. This gene is translated to the constitutively active tyrosine kinase BCR-ABL1, the determinant of CML pathophysiology [1]. Treatment of CML was revolutionized in 2001, when the first BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib was introduced [2]. Numerous studies with TKIs revealed that a deep, early molecular response leads to improved long-term outcome for patients [3, 4]. Although imatinib is extremely effective by slowing down disease progression and modulating symptoms, around 30% of patients do not respond sufficiently or develop drug resistances to standard therapy [4]. BCR-ABL1-dependent resistances are mainly based on amplifications or mutations in the fusion gene leading to elevated kinase activity or to attenuation of imatinib binding [1]. Although these BCR-ABL1-dependent mechanisms are more frequent and led to development of second and third generation TKIs, resistances can also occur independently of the fusion gene [5, 6]. Several mechanisms have been identified including activation of alternative oncogenic pathways as WNT, JAK-STAT, autophagy, and Hedgehog signaling, alterations of drug influx and efflux transporters, clonal evolution and epigenetic dysregulation, defective DNA repair mechanisms and genomic instability, inherently resistant stem cells, changes in bone marrow stromal microenvironment, and elevated levels of inhibitors of apoptosis proteins [5, 6]. Additionally, microRNAs (miRNAs), short non-coding RNAs, which post-transcriptionally modulate gene expression via mRNA degradation or translational repression, have been implicated in CML progression, response to treatment and development of TKI resistances [7, 8].

As these resistances are a major challenge in CML treatment, predictive markers are desirable to improve the selection of appropriate therapy regimes and thereby patient outcome. MiRNAs as potent regulators of gene expression are discussed as biomarkers for diagnosis, progression and drug response in various tumor types [9,10,11,12]. Previous studies analyzing miRNA expression patterns of treatment-naïve CML patients at diagnosis aiming to predict TKI resistances included only 8–12 patients and led to contradictory results. While Lavrov et al. did not find any significant differences in miRNA expression pattern between non-responding and responding patients to TKI therapy, the other three studies suggested selected miRNAs as potential predictive biomarkers for TKI response [9,10,11,12]. However, even these suggested miRNAs were inconsistent between the studies. Larger studies including more treatment-naïve CML patients are needed to clarify if selected miRNAs may have the potential to discriminate between non-responders and responders and may be considered as predictive biomarkers for TKI resistance in future.

The aim of the present study was to provide a more comprehensive miRNA expression data set of 28 peripheral blood and 17 bone marrow samples from treatment-naïve CML patients without mutations in BCR-ABL1. A hypothesis-free approach was selected starting with high-throughput screening of miRNA expression to identify possible new or additional miRNAs with considerable expression differences between non-responders and responders to imatinib therapy. Thereafter, the potential functional impact of the identified miRNAs was analyzed by studying their binding ability to the 3′-UTRs of critical target genes associated with CML, CML-related pathways and chemoresistance using reporter gene assays.

Methods

Patient samples

Peripheral blood (n = 28) or bone marrow samples (n = 17) were obtained from 45 CML patients at the time of diagnosis by the Department of Medicine II, University Hospital Schleswig–Holstein, Kiel, Germany. The patients (28 males and 17 females) had a median age of 57.9 years. (range: 19–86 years.; median age responders 57.3 years., non-responders 58.7 years). In all patients BCR-ABL fusion transcripts were confirmed by consensus multiplex PCR and breakpoint determination, DNA Sanger sequencing of the fusion transcript was used to verify that none of the patients did carry common mutations in the BCR-ABL1-gene, which are known to cause imatinib resistance [13]. According to disease progression after sampling, patients were classified into responders (n = 26) or non-responders (n = 19). Response was defined as patients reaching a major molecular response (BCR-ABL1/ABL1 ratio < 1 × 10–3) within the first 18 months of therapy, whereas non-responders did not reach a major molecular response within this time interval [14]. Individual patients’ parameters are summarized in Table 1. The study was conducted according to the guidelines of Helsinki and was approved by the Ethics Committee of the Medical Faculty of Kiel University, Germany (reference number: D 426/03). Each patient gave his written informed consent.

Table 1 Patient’s characteristics including sample type, BCR-ABL1/ABL1 ratio before/after imatinib therapy for responders (R) and non-responders (NR)
Full size table

Determination of miRNA expression profiles

White blood cells from patients’ peripheral blood or bone marrow samples were purified using the QIAmp RNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers protocol and stored in RLT-buffer (Qiagen, Hilden, Germany) or trizole (ThermoFisher Scientific, Waltham, USA) at −80 °C prior to use. Total RNA was isolated from the leukocyte fraction using the mirVana miRNA Isolation Kit (ThermoFisher Scientific) according to manufacturer’s protocol. 200 ng of total RNA were reversely transcribed using Human Megaplex Primer Pools A v.2.1 and TaqMan microRNA Reverse Transcription Kit (ThermoFisher Scientific) on the GeneAmp PCR system 9700 (ThermoFisher Scientific) according to the manufacturer’s recommendations. After pre-amplification of cDNA according to manufacturer’s protocol, the pre-amplified cDNA was loaded on TaqMan Human MicroRNA Cards A v2.1 and analyzed on the ABI Prism 7900HT Sequence Detection System (ThermoFisher Scientific) with default cycling conditions. Expression data of screened miRNAs exhibiting Ct-values < 35 were included into further analysis. MiRNA expression levels were analyzed using the ΔΔCt method with U6snRNA as endogenous control [15]. Fold changes were calculated based on the ratio of the median of non-responders compared to the median of responders for the subsets of samples derived from peripheral blood or bone marrow.

Target prediction

An in silico target prediction was performed using different prediction tools including TargetScan 7.2 [16], microRNA.org [17], MicroCosm Targets [18] and DIANA-microT [19] to identify potential target genes of miRNAs showing p-values ≤ 0.05 in both sample origins or the lowest overall p-value comparing non-responders to responders (hsa-miR-142-5p, hsa-miR-365a-3p). Predicted targets were analyzed for their role in CML, leukemia and cancer pathways using the Gene Name Batch Viewer of the DAVID Functional Annotation Tool (DAVID Bioinformatics Resources 6.7) [20], which allows a summarized overview of function and pathway involvement for every target gene. Target genes of interest were further evaluated by literature search focusing on their involvement in CML, leukemia, CML linked pathways and chemoresistance with a minimum of 10 publications each. These genes were transferred to further functional analysis, namely: ABL2 (abelson murine leukemia viral oncogene homolog 2 [21,22,23,24,25,26,27,28,29,30]), cKIT (KIT proto-oncogene receptor tyrosine kinase [4, 31,32,33,34,35,36,37,38,39]), MCL1 (myeloid cell leukemia 1 [7, 40,41,42,43,44,45,46,47,48]), SHC4 (src homology 2 domain containing family, member 4 [4, 23, 49,50,51,52,53,54,55,56]) and SRI (sorcin [50, 57,58,59,60,61,62,63,64,65]).

Cloning of luciferase vectors for reporter gene assays

For in vitro validation of in silico predicted interactions between miRNAs (hsa-miR-142-5p, hsa-miR-365a-3p) and selected target genes, luciferase reporter gene assays were performed. Predicted miRNA binding regions of the 3′-UTRs of selected target genes ABL2, cKIT, MCL1, SHC4, SRI were cloned into the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, Mannheim, Germany) using the In-Fusion HD Cloning Kit (Takara Bio USA, Mountain View, CA, USA) with gene-specific primers purchased from Sigma Aldrich, Missouri, USA, according to the manufacturers recommendations (for details see Additional file 1: Table S1).

Transient transfection and luciferase reporter gene assays

The miRNA mimics (pre-miRs) used for reporter gene assay analysis were purchased from Ambion (ThermoFisher Scientific): pre-miR-142-5p (PM10979), pre-miR-365a-3p (PM11133) and pre-miR miRNA Precursor Negative Control #1 (AM17110). For reporter gene assay experiments, HepG2 cells (DMSZ, Braunschweig, Germany) were cultured as previously described [66]. Per well of a 96-well plate, a 20 µl transfection complex consisting of OptiMEM (Gibco, ThermoFisher Scientific), siPort NeoFX transfection reagent (ThermoFisher Scientific), reporter gene plasmid DNA (100 ng/well) and the selected pre-miR or pre-miR negative control were added in two concentrations (10 nM or 25 nM) according to the manufacturer protocol. Each well was covered with 80 µl of HepG2 cell suspension (100,000 cells/ml). Medium was replaced with fresh growth medium 24 h after transfection. 48 h after transfection, reporter gene activities were measured using dual-luciferase reporter assay system (Promega, Mannheim, Germany) on a Veritas microplate luminometer (Tuner Biosystems, Sunnyvale, CA, USA). To analyse the effect of the respective miRNA on the target gene vectors, first, relative reporter gene activities were obtained by normalizing the firefly to the renilla luciferase signal in each well. Next, the firefly/renilla luciferase ratio of cells co-transfected with target gene vector and pre-miR of interest was normalized to the total median of firefly/renilla ratio of cells co-transfected with target gene vector and pre-miR negative control. The same calculation was done for firefly/renilla ratios of cells co-transfected with empty vector and pre-miR of interest or pre-miR negative control. Finally, the relative luciferase activities of target genes were normalized to the relative luciferase activities of empty vectors to exclude potential indirect miRNA-mediated effects on reporter gene promoter activity [67].

Site-directed mutagenesis

As proof of principle for selected miRNA-target gene pairs showing a significant downregulation of relative reporter gene signal compared to the empty vector, site-directed mutagenesis of the predicted miRNA binding regions was performed to confirm the exact position of the miRNA binding site in the target 3′-UTR sequence. For this, four to six bases in the binding site were mutated. Site-directed mutated plasmid vectors were obtained from GenScript (New Jersey, USA) for the following binding regions of miR-142-5p in ABL2 3′-UTR (MUT 1: TTTA → GTAC, mutation site: 3918–3921 bp; MUT 2: TTTA → CGCG, mutation site: 4247–4250 bp) and in MCL1 3′-UTR (MUT 1: TTTA → CGCG, mutation site: 2230–2233 bp) and for miR-365a-3p binding regions in cKIT (MUT 1: AGGG → CATA, mutation site: 1143–1146 bp; MUT 2: GGCATT → TATGCG, mutation site: 749–754 bp).

Statistics

Differences in expression levels and in reporter gene activity were calculated using Mann–Whitney U-tests (GraphPad Software, version 7.04, San Diego California, USA). P-values < 0.05 were considered as statistically significant.

Results

MiRNA expression profiling of treatment-naïve CML patients revealed differences between patients non-responding or responding to imatinib therapy

MiRNA expression profiles of treatment-naïve CML patients in chronic phase not responding to imatinib in the course of their treatment were compared to the profiles of treatment-naïve patients, who responded to therapy (for details see Table 1). Molecular response was defined as BCR-ABL1/ABL1 ratio < 1 × 10–3 within the first 18 months of therapy, whereas non-response was defined by a lack of major molecular response within this time interval. Out of a total of 374 measured miRNAs, 128 miRNAs exhibited Ct-values < 35 in the entire set of samples and were included for further analysis.

The analysis was performed separately for the two sample specimens, peripheral blood (PB, n = 28) and bone marrow (BM, n = 17). For the subset of samples drawn from peripheral blood, two miRNAs (miR-331-5p, miR-636) were significantly upregulated (fold change: 1.83, 2.55; p < 0.05), while six miRNAs (miR-142-3p, miR-142-5p, miR-193a-3p, miR-365a-3p, miR-545-3p, miR-888-5p) showed a significant lower expression in non-responders compared to responders (fold change range: −1.99 to −1.62; p < 0.05; Fig. 1). The analysis of bone marrow samples revealed 14 significantly downregulated miRNAs (let-7b-5p, miR-125b-5p, miR-130a-3p, miR-134-5p, miR-142-5p, miR-210-3p, miR-320a-3p, miR-376a-3p, miR-376c-3p, miR-411-5p, miR-423-5p, miR-542-5p, miR-642a-5p, miR-874-3p) in non-responders compared to responders (fold change range: −15.42 to −1.99; p < 0.05). MiR-142-5p was the only miRNA, which was significantly downregulated in both sample specimens (PB: fold change: 1.96; p = 0.02; BM: fold change: -8.63; p < 0.01) and thus appeared as most robust candidate for discrimination of non-responders from responders in our patient cohort (Fig. 1a–c). In addition, miR-365a-3p showing the most significant downregulation in peripheral blood samples of non-responders (fold change: −1.96; p < 0.01) and a tendency of lower expression levels in the non-responder group of the bone marrow sample (fold change: −7.96; p = 0.15) was chosen as additional candidate (Fig. 1a, b, d).

Fig. 1
figure 1

MiRNA expression profiling revealed differences between treatment-naïve CML patients non-responding vs. responding to imatinib therapy. a The miRNA expression profiling revealed significant differences between imatinib non-responders (NR) and responders (R) in peripheral blood and bone marrow samples. Statistical significances between NR and R were calculated using Mann–Whitney-U-tests. b Differences in expression levels between NR and R are presented as fold changes of relative miRNA expression levels for peripheral blood and bone marrow samples. For miR-142-5p (c) and miR-365a-3p (d) the normalized expression values are presented here, separately for the comparison of NR and R in peripheral blood and in bone marrow. MiRNA expression levels were normalized to U6snRNA using the 2−ΔΔct method. Data are shown as median ± interquartile range

Full size image

Identification of potential interactions between miR-142-5p and miR-365a-3p and CML-related target genes

As the expression profiles particularly of miR-142-5p and of miR-365a-3p indicated that these two miRNAs could be candidates which are able to discriminate non-responders from responders in two different samples specimens, we aimed to investigate if the miRNAs have the potential to interact with target genes known to be involved in CML progression or drug resistance [68,69,70]. For this purpose, an in silico target prediction was performed using various prediction algorithms. The analysis resulted in 6004 potential target genes for miR-142-5p and in 7442 potential targets for miR-365a-3p. To focus only on the potential target genes associated with CML and drug resistance, all genes from the target prediction analysis were transferred to the Gene Name Batch Viewer of DAVID Annotation Tool and filtered for the key terms ‘CML’, ‘leukemia’, ‘chemoresistance’ and ‘pathways in cancer’. Subsequently, an extensive literature search was performed to evaluate the role of the suggested genes in context with CML. The following resulting five potential target genes with clear links to CML and CML-related pathways, cell survival and chemoresistance were selected for further interaction analysis via reporter gene assays: cKIT, a survival factor in CML cells, whose mutations contribute to poorer prognosis of CML patients, MCL1, coding for an anti-apoptotic protein often overexpressed in CML, ABL2, known to be upregulated in CML disease progression and potentially contributing to imatinib resistance, SHC4, involved in activation of BCR-ABL1 and cKIT downstream pathways, and SRI associated with multidrug resistance in various tumour types (for further references, see Additional file 1: Table S2) [21, 31, 40, 49, 57].

Validation of CML-related genes as direct targets of miR-142-5p and miR-365a-3p

Reporter gene assays were performed to evaluate the potential functional impact of miR-142-5p and miR-365a-3p on the selected CML-related target genes ABL2, cKIT, MCL1, SHC4 and SRI by analyzing the miRNA binding ability to target gene 3′-UTRs. The assays were conducted with two different concentrations of miR-142-5p and miR-365a-3p precursors and 3′-UTR-vector constructs of the respective target genes. To verify that decreases in reporter gene signals were originated from specific interactions between miRNA and predicted target sites, mutagenesis of target sites for selected miRNA-target gene pairs were performed including miR-142-5p—ABL1 3′-UTR and—MCL1 3′-UTR, and miR-365a-3p—cKIT 3′-UTR.

ABL2

In the reporter gene assays, the 3′-UTR of the non-receptor tyrosine kinase ABL2 was identified as target of miR-142-5p showing a significant repression of normalized reporter gene activity by 18% (10 nM, p < 0.0001) and 26% (25 nM, p < 0.0001) compared to empty vector control (Fig. 2a). As in silico tools predicted two binding sites for miR-142-5p in the ABL2 3′-UTR, mutations at these positions were introduced to verify the binding to these sites was responsible for the observed effect (Fig. 2b–d). While mutation at positions 3918–3921 bp (MUT 1) alone did not completely reverse the effect of the miRNA binding (Fig. 2b), the combination of MUT 1 together with mutations at positions 4247–4250 bp (MUT 2) led to a complete abolishment of the inhibitory effect of miR-142-5p (Fig. 2c).

Fig. 2
figure 2

Reporter gene assays indicated a direct interaction of miR-142-5p with the ABL2 3′-UTR. Vectors containing the 3′-UTR of ABL2 were co-transfected with pre-miR-142-5p in two concentrations (10 nM, 25 nM). Reporter gene activities were measured 48 h after transfection. a Co-transfection of vector containing the ABL2 3′-UTR (WT) with miR-142-5p resulted in a suppression of relative reporter gene activity by 18% [10 nM] and 26% [25 nM]. b Introduction of mutation (MUT 1) into the predicted binding site at positions 3918–3921 bp of ABL2 3′-UTR led to a minor effect. c Combination of MUT 1 with mutations in the predicted binding site at positions 4247–4250 bp (MUT 2) abolished the inhibitory effect of the miRNA. d Predicted interactions of miR-142-5p with ABL2 3′-UTR is indicated and mutated bases for MUT 1 and MUT 2 are highlighted in gray. All reporter gene activities (n ≥ 12 in 3 independent experiments) were normalized to activities from cells transfected with respective 3′-UTR target sequence vectors and pre-miR negative control (median ± interquartile range). Activities are shown relative to empty control vector (c) identically transfected and normalized as 3′-UTR target sequence vectors. Mann–Whitney U-test; *p ≤ 0.05, ***p ≤ 0.001

Full size image

MCL1

The 3′-UTR of MCL1 was also identified as target of miR-142-5p. The miRNA led to a significant reduction of normalized reporter gene activity by 16% (10 nM, p < 0.0001) and 23% (25 nM, p < 0.0001) compared to empty vector control (Fig. 3a). This interaction was confirmed by experiments with a mutated miR-142-5p binding region (positions 2230–2233 bp in MCL1 3′-UTR (MUT 1)), where the inhibitory effect of the miRNA was abolished (Fig. 3b–c).

Fig. 3
figure 3

Reporter gene assays revealed a concentration-dependent interaction of miR-142-5p on MCL1 3′-UTR. MCL1 3′-UTR containing vectors were co-transfected with pre-miR-142-5p in two concentrations (10 nM, 25 nM). After 48 h, reporter gene activities were measured. a Normalized reporter gene activity on MCL1 3′-UTR (WT) was repressed by miR-142-5p 16% [10 nM] and 23% [25 nM]. b Mutagenesis of the predicted seed region 2230–2233 bp (MUT 1) abolished this inhibitory effect. c The prediction of miR-142-5p binding to MCL1 3′-UTR are illustrated including mutated bases highlighted in gray. All reporter gene activities (n ≥ 12 in 3 independent experiments) were normalized to activities of cells transfected with respective 3′-UTR target sequence vectors and pre-miR negative control (median ± interquartile range). Activities are shown relative to empty control vector (c) identically transfected and normalized as 3′-UTR target sequence vectors. Mann–Whitney U-test; ***p ≤ 0.001

Full size image

cKIT

For the receptor tyrosine kinase cKIT, our analysis indicated interactions with both miRNAs, miR-142-5p and miR-365a-3p, respectively. MiR-142-5p significantly repressed the normalized reporter gene activity by 39% (10 nM, p = 0.0022) and 52% (25 nM, p = 0.0022; Fig. 4a, b) and miR-365a-3p by 24% (10 nM, p < 0.0001) and 24% (25 nM, p < 0.0001; Fig. 4c–f).

Fig. 4
figure 4

Reporter gene assay determined interactions of miR-142-5p and miR-365a-3p with cKIT 3′-UTR. Vectors containing cKIT 3′-UTR were co-transfected with pre-miR-142-5p and pre-miR-365a-3p, each in concentrations 10 nM and 25 nM. Measurement of reporter gene activities was performed 48 h after transfection. a Relative reporter gene activity of wild type cKIT 3′-UTR (WT) was repressed by miR-142-5p by 39% [10 nM] and 52% [25 nM]. b Predicted interactions of miR-142-5p within the binding region of cKIT 3′-UTR are illustrated here. c Co-transfection of cKIT 3′-UTR with miR-365a-3p resulted in repression of relative reporter gene activity by 24% [10 nM] and 24% [25 nM]. d The introduction of mutations in the binding region at positions 1143–1146 bp (MUT 1) slightly abolished effect on reporter gene activity. e Additional introduction of mutated bases at positions 749–754 bp (MUT 2) led to neutralization of the inhibitory effects of miR-365a-3p. f Predicted interactions of miR-365a-3p with cKIT 3′-UTR are depicted with mutated bases highlighted in gray. All reporter gene activities (n ≥ 12 in 3 independent experiments) were normalized to activities of cells transfected with respective 3′-UTR target sequence vectors and pre-miR negative control (median ± interquartile range). Activities are shown relative to empty control vector (c) identically transfected and normalized as 3′-UTR target sequence vectors. Mann–Whitney U-test; **p ≤ 0.01, ***p ≤ 0.001

Full size image

As proof of principle, the predicted miRNA binding site in cKIT 3′-UTR were representatively analyzed for miR-365a-3p. While a mutation in the predicted binding region at positions 1143–1146 bp of cKIT 3′-UTR (MUT 1) had only slight effects (Fig. 4d), the combination with mutations in the binding region at 749–754 bp (MUT 2) reversed the inhibitory effect of miR-365a-3p (Fig. 4e).

SRI

SRI was identified as a target of miR-142-5p, since it repressed SRI 3′-UTR reporter gene activity by 26% (10 nM, p = 0.0051) and 8% (25 nM, p = 0.0242; Fig. 5).

Fig. 5
figure 5

Reporter gene assays showed an interaction of miR-142-5p with SRI 3′-UTR. Co-transfection of the vectors containing the 3′-UTR of SRI with pre-miR-142-5p was performed in two concentrations (10 nM and 25 nM). 48 h after transfection, reporter gene activities were measured. a MiR-142-5p repressed reporter gene activity of wild type SRI 3′-UTR (WT) by 26% [10 nM] and 8% [25 nM]. b Predicted interaction of miR-142-5p with SRI 3′-UTR. All activities (n ≥ 12 in 3 independent experiments) were normalized to activities of cells transfected with respective 3′-UTR target sequence vectors and pre-miR negative control (median ± interquartile range). Activities are shown relative to empty control vector (c) identically transfected and normalized as 3′-UTR target sequence vectors; Mann–Whitney U-test; **p ≤ 0.01, *p ≤ 0.05

Full size image

SHC4

Although miR-142-5p was predicted in silico to interact with the SHC4 3′-UTR, reporter gene experiments could not confirm any in vitro interaction (Additional file 1: Figure S1).

Discussion

The present analysis provides miRNA expression data of 28 peripheral blood and 17 bone marrow samples from treatment-naïve CML patients at diagnosis with the aim to evaluate, if selected miRNAs could discriminate between patients being responder or non-responder to imatinib therapy, as suggested by earlier studies [9,10,11]. In addition, we aimed to link the identified miRNAs to oncogenic signaling pathways critical for development of therapy resistance. MiR-142-5p was significantly lower expressed in non-responders compared to responders in both sample specimens. For miR-365a-3p, a significantly lower expression was observed in PB of non-responders and a trend for lower expression in BM samples. Moreover, the miRNAs were identified to interact with the 3′-UTRs of the known CML-related oncogenes ABL2, cKIT, MCL1 and SRI.

As drug resistance still remains a challenge in CML treatment, predictive biomarkers would help to optimize patients’ therapy. MiRNAs are frequently discussed as potential candidates for these biomarkers [12, 71, 72]. So far, three out of the four studies analyzing miRNA expression pattern of treatment-naïve CML patients at time of diagnosis suggested selected miRNAs as potential predictive markers for TKI resistance [9,10,11,12]. However, these studies showed varying results. Jurkovicova et al. found a total of 70 differentially expressed miRNAs between treatment-naïve non-responders and responders, José-Enériz et al. identified 19 miRNAs and Mosakhani et al. detected only one miRNA, miR-181c-5p, to be significantly down-regulated in non-responders compared to responders [9,10,11]. Furthermore, Lavrov et al. did not find any miRNA, whose expression pattern could discriminate between non-responds and responds to TKI therapy at time of diagnosis [12]. This inconsistency of study results might be based on factors such as differences in study design including diverse sample origin (peripheral blood or bone marrow), differences in patient cohorts, e.g. age or gender as well as the usage of various analysis platforms [73]. Another specifically important factor for the discordance in study results might be the low number of study subjects (n = 8–12), which may lead to small sample size errors characterized by increasing numbers of false positive, but also false negative results [73].

To target these shortcomings, the present study included larger numbers of samples for both major sample origins (peripheral blood and bone marrow) obtained from treatment-naïve CML patients in chronic phase classified as non-responders or responders to imatinib therapy according to molecular response during the first 18 months of treatment initiation. An unbiased, hypothesis-free approach was selected for miRNA analysis, which provided not only the possibility to confirm miRNAs described in earlier studies but enables also to identify new or additional ones. In contrast to earlier studies, we compared the miRNA expression pattern of both sample specimens with the aim to identify miRNAs whose expression pattern discriminates both patient’s groups irrespective of the sample origin, an important characteristic for a potential future biomarker. As expected, samples from both specimens exhibited differences in their miRNA expression pattern between non-responders and responders. However, by our approach we were able to identify miR-142-5p as most robustly expressed miRNA showing significant expression differences in both, peripheral blood and bone marrow samples. Although the expression differences were modest, they could substantially influence cellular processes [74]. This is also supported by the recent study of Alves et al. in CML patients, which described slight miRNA expression differences between TKI non-responders and responders at diagnosis that became more pronounced after six and twelve months of therapy [75].

While miR-142-5p is described as master regulator of hematopoiesis, its role in cancer seems to depend on the specific context [70]. In non-small cell lung and breast cancer tissue, an overexpression of miR-142-5p was associated with cell growth and progression, whereas low expression levels were observed in CLL [70, 76, 77]. In our study, miR-142-5p was downregulated in peripheral blood and bone marrow samples of non-responders, along with miR-let-7b-5p, miR-320a-3p and miR-130a-3p, all described to target CML relevant oncogenes as BCR-ABL1 [7, 78]. Decreased expression levels of miR-365a-3p seem also to result in various effects depending on the cancer type. While miR-365a-3p inhibits carcinogenesis in epidermal squamous cell carcinomas, it has been characterized as onco-miR in laryngeal squamous cell carcinoma [68, 69].

In the second part of this study, initial functional analyses were performed to investigate the potential impact of these two miRNAs on CML signaling pathways. After identification of target genes of miR-142-5p and miR-365a-3p with link to CML pathogenesis and therapy resistance, reporter gene assays were performed. MiR-142-5p was confirmed to interact with the ABL2, MCL1, cKIT and SRI 3′-UTR, while miR-365a-3p, found as significant marker in peripheral blood samples, was identified to interact with the 3′-UTR of cKIT. These miRNA-target gene interactions, together with the low expression levels of miR-142-5p and miR-365a-3p in patients non-responding to imatinib therapy, suggest a tumor suppressor role in CML context.

We integrated our findings into the complex CML pathway network and tried to propose potential mechanisms involving miR-142-5p and miR-365a-3p (Fig. 6). ABL2, a member of the Abelson family of non-receptor tyrosine kinases, was identified as target of miR-142-5p in the present study and is known to be upregulated in CML disease progression [21,22,23]. By regulating cytoskeleton rearrangement, invasiveness of neoplastic cells and expression of matrix metalloproteinases (MMPs), it plays a substantial role in the BCR-ABL1 signaling network and is described to be involved in the acquisition of chemotherapy resistance in diverse solid tumors [23, 24].

Fig. 6
figure 6

Hypothesized role of miR-142-5p and miR-365a-3p in CML signaling. Schematic representation of the hypothesized effect of miR-142-5p and miR-365a-3p (indicated by red boxes) on CML linked pathways by targeting ABL2, cKIT, MCL1 and SRI (indicated by red circles). Ligands as EGFR, FGFR, PDGFR and SCF bind to cKIT and activate downstream signaling cascades, including RAS/RAF/MEK/ERK, PI3K/AKT and JAK2 [32,33,34]. In the RAS/RAF/MEK/ERK pathway [1], the GRB2/SOS complex activates a phosphorylation cascade that regulate proliferation and apoptosis[52]. PI3K/AKT pathway (2) is activated e.g. by growth factors and stimulates PI3K, mediating the conversion of PIP2 to PIP3. PIP3 translocates AKT to plasma membrane, where AKT regulates numerous proteins associated with proliferation, metabolism, apoptosis, including NFκB inducing inflammatory cytokines like IL-6[51, 88]. IL-6 activates the JAK/STAT pathway (3) where STAT translocates to nucleus, stimulating transcription of genes linked to cell proliferation, differentiation, survival and immune function as VEGF and BCL-2-family members like MCL1[43]. Upregulation of cKIT due to decreased miR-142-5p and miR-365a-3p expression might result in augmented proliferation, differentiation and survival. Downregulation of miR-142-5p might lead to upregulation of MCL1, facilitating cell survival. Both ABL1 and ABL2 stimulate RAC, Cortactin/N-WASP and WAVE/ABI1 (4) promoting migration and invasion through lamellipodia protrusion and actin/myosin filament contraction[24]. Downregulation of miR-142-5p would support metastasis through upregulation of ABL2. Sorcin regulates JAK/STAT, RAS/RAF/MEK/ERK, PI3K/AKT pathways and MMP expression, hence downregulation of miR-142-5p might increase sorcin and promote proliferation, differentiation, cell motility and survival[50, 62, 63]. Selection of miRNAs known to be linked to CML are illustrated in dashed boxes. MiR-29b-3p, miR-30a-5p, miR-30e-5p, miR-203-3p, miR-320a-3p, miR-424-5p, miR-451a and miR-23a-3p target BCR/ABL1, while miR-23a-3p, let-7b-5p and miR-130a-3p inhibit RAS [6, 7, 78]. MiR-130a-3p furthermore regulates BCL-2 and MCL1 expression [7]. Besides inhibiting BCL-2, miR-17/92 targets JAK2/STAT5 [7]. MiR-146a-5p and miR-150-5p contribute to CML carcinogenesis by upregulating MMPs [89]. Full gene names listed in Additional file 1: Table S3

Full size image

MiR-142-5p was also identified to interact with MCL1, a member of the anti-apoptotic Bcl-2 family, which is involved in the JAK/STAT, RAS/RAF/MEK/ERK and STAT5 signaling pathways [41]. MCL1 is a BCR-ABL1-dependent survival factor, constitutively expressed in primary CML cells, that has been implicated in CML pathogenesis, whereas downregulation of MCL1 by antisense oligonucleotides is associated with increased sensitivity of K562 cells to imatinib [40]. In various cancer contexts, MCL1-overexpression was described as possible key factor for therapy resistances [41, 42].

SRI is also linked to multidrug resistances in a variety of tumor types and was here also identified as target of miR-142-5p [58,59,60]. An overexpression of the gene product sorcin was correlated to poor clinical outcome and suggested to contribute to drug resistance of AML patients [61]. Sorcin contributes to tumor growth and metastasis via regulation of the JAK/STAT, RAS/RAF/MEK/ERK and PI3K/AKT pathways, as well as via regulation of MMP expression [50, 62, 63, 79].

Moreover, cKIT was identified in the present study as a target of both significantly downregulated miRNAs, miR-142-5p and miR-365a-3p. Beside BCR-ABL1 inhibition, imatinib provides inhibitory effects on cKIT signaling, which is discussed to be important to achieve the maximal effect of the drug [4, 80]. cKIT induces the PI3K/AKT pathway, which leads to NF-κB activation, antiapoptotic and pro-proliferative effects [32]. cKIT is also known to induce the RAS/RAF/MEK/ERK and JAK2 pathways and thereby regulates proliferation and cell death [33, 34].

Only for the miRNA–gene pair miR-142-5p–SHC4, results of reporter gene assays did not indicate any interaction. Such a finding is not unexpected, as even target prediction algorithms may have a false positive rate of 20–50%. This result rather highlights the need of experimental validation of in silico predicted miRNA–gene interactions [81].

Taken together, potential mechanisms, how decreased expression of miR-142-5p and miR-365a-3p might contribute to development of imatinib resistance in CML patients could be suggested based on our findings and on literature data. However, it must be taken into account that these interaction data were generated in an in vitro setup. Therefore, further functional studies are needed, including the quantification of mRNA and protein levels of target genes and its affected pathways in patients. Due to lack of patient material, it was not possible to perform these experiments in the present study.

Before truly considering these miRNAs as candidates for predictive biomarkers, additional aspects need to be considered. Although we were able to include more patients than previous studies, the overall sample size is still small, and a certain degree of variability in miRNA expression levels was observed. Reasons for this variability might be the general biological diversity of patients, differences in miRNA expression pattern due to diverse cells compositions in sample specimens and the intratumoral heterogeneity in CML [82, 83]. As it is shown that expression levels of selected miRNAs change across different CML phases, one may assume that even within the chronic phase dynamic changes on miRNA expression pattern might occur [83]. These aspects need to be targeted in further studies. It is crucial to fully understand the role of miRNAs in TKI resistance before further consideration as potential candidates for predictive biomarkers. This is of particular importance, because miRNAs lack an exclusive link to one target gene or disease and thus lack the high specificity, which is a requested feature of biomarkers [72, 84]. Future studies should also include further investigations on the role of long non-coding RNAs in imatinib resistance as studies indicate that imatinib resistance can be modulated by long-non coding RNAs which target miRNAs thereby changing the expression of target associated with drug resistance like ABCB1 or ABCC2 [85,86,87].

Conclusion

In summary, this comprehensive analysis provides first evidence for a potential tumor suppressor role of miR-142-5p and less pronounced of miR-365a-3p in CML progression and TKI drug response. Furthermore, it highlights also the need of further large-scale prospective, randomized trials to replicate findings of miRNA expression analysis and thereby identify the most robust miRNA candidates which might have a potential for future predictive biomarkers for TKI resistance.

Availability of data and materials

Data available on request.

References

  1. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447–599.

    Article  PubMed  Google Scholar 

  2. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.

    Article  PubMed  Google Scholar 

  3. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14(3):141–54.

    Article  CAS  PubMed  Google Scholar 

  5. Meenakshi Sundaram DN, Jiang X, Brandwein JM, Valencia-Serna J, Remant KC, Uludağ H. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. Drug Discov Today. 2019;24(7):1355–69.

    Article  CAS  PubMed  Google Scholar 

  6. Kotagama K, Chang Y, Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev Res. 2015;76(6):278–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yeh C-H, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Wienholds E, Plasterk RHA. MicroRNA function in animal development. FEBS Lett. 2005;579(26):5911–22.

    Article  CAS  PubMed  Google Scholar 

  9. San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, Garate L, Martin V, Cordeu L, et al. MicroRNA expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8(1):69.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Jurkovicova D, Lukackova R, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, et al. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia. Neoplasma. 2015;62(6):949–57.

    CAS  PubMed  Google Scholar 

  11. Mosakhani N, Mustjoki S, Knuutila S. Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet. 2013;6(1):27.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Lavrov AV, Chelysheva EY, Adilgereeva EP, Shukhov OA, Smirnikhina SA, Kochergin-Nikitsky KS, et al. Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients. BMC Med Genomics. 2019;12(2):37.

    PubMed  PubMed Central  Google Scholar 

  13. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia. 2003;17(12):2318–57.

    CAS  PubMed  Google Scholar 

  14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–8.

    CAS  Google Scholar 

  15. Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:05005.

    Article  Google Scholar 

  16. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008;36:149–53.

    Article  CAS  Google Scholar 

  17. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36:154–8.

    Article  CAS  Google Scholar 

  18. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et al. DIANA-microT web server v50: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41:169–73.

    Article  Google Scholar 

  19. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.

    Article  CAS  Google Scholar 

  20. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(8):2794–9.

    CAS  PubMed  Google Scholar 

  21. Ha BH, Simpson MA, Koleske AJ, Boggon TJ. Structure of the ABL2/ARG kinase in complex with dasatinib. Acta Crystallogr Sect F. 2015;71:443–8.

    CAS  Google Scholar 

  22. Wang J, Pendergast AM. The emerging role of ABL kinases in solid tumors. Trends Cancer. 2015;1(2):110–23.

    PubMed  PubMed Central  Google Scholar 

  23. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Publ Gr. 2013;13(8):559–71.

    CAS  Google Scholar 

  24. Cong XL, Li B, Yang RC, Feng SZ, Chen SJ, Han ZC. Enhanced growth suppression of Philadephia leukemia cells by targeting bcr3/abl2 and VEGF through antisense strategy. Leukemia. 2005;19(9):1517–24.

    CAS  PubMed  Google Scholar 

  25. Gil-Henn H, Patsialou A, Wang Y, Warren MS, Condeelis JS, Koleske AJ. Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo. Oncogene. 2013;32(21):2622–30.

    CAS  PubMed  Google Scholar 

  26. Yokota A, Hirai H, Shoji T, Maekawa T, Okuda K. Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo. Leukemia. 2017;31(12):2742–51.

    CAS  PubMed  Google Scholar 

  27. Salah E, Ugochukwu E, Barr AJ, von Delft F, Knapp S, Elkins JM. Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a Type I inhibitor of the triazole carbothioamide class. J Med Chem. 2011;54(7):2359–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Qin X, Wan Y, Wang S, Xue M. MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2. Drug Des Devel Ther. 2015;2016(10):71–9.

    Google Scholar 

  29. Qiang X-F, Zhang Z-W, Liu Q, Sun N, Pan L-L, Shen J, et al. miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J Cell Biochem. 2014;115(7):1269–76.

    CAS  PubMed  Google Scholar 

  30. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia—potential clinical significance. Leukemia. 2002;16(2):170–7.

    Article  CAS  PubMed  Google Scholar 

  31. Airiau K, Mahon F-X, Josselin M, Jeanneteau M, Belloc F. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. Cell Death Dis. 2013;4(10):e827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen L-T, Chen C-T, Jiaang W-T, Chen T-Y, Butterfield JH, Shih N-Y, et al. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT–driven myeloid leukemia. Mol Cancer Ther. 2016;15(10):2323–33.

    Article  CAS  PubMed  Google Scholar 

  33. Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, et al. JAK 2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood. 2002;87(9):3688–93.

    Article  Google Scholar 

  34. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127(1):294–9.

    Article  CAS  PubMed  Google Scholar 

  35. Belloc F, Airiau K, Jeanneteau M, Garcia M, Guérin E, Lippert E, et al. The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells. Leukemia. 2009;23(4):679–85.

    Article  CAS  PubMed  Google Scholar 

  36. Babaei MA, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016;2016(10):2443–599.

    Article  Google Scholar 

  37. Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA III, Sundaramoorthi R, et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 2005;106(1):227–34.

    Article  CAS  PubMed  Google Scholar 

  38. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139–45.

    CAS  PubMed  Google Scholar 

  39. Aichberger KJ, Mayerhofer M, Krauth M-T, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105(8):3303–11.

    Article  CAS  PubMed  Google Scholar 

  40. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009;66(8):1326–36.

    Article  CAS  PubMed  Google Scholar 

  41. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981–9.

    Article  CAS  PubMed  Google Scholar 

  42. Wang S-W, Sun Y-M. The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer (review). Int J Oncol. 2014;44(4):1032–40.

    Article  CAS  PubMed  Google Scholar 

  43. Alizadeh S, Azizi SG, Soleimani M, Farshi Y, Khatib ZK. The Role of MicroRNAs in myeloproliferative neoplasia. Int J Hematol Stem Cell Res. 2016;10(3):172–85.

    Google Scholar 

  44. da Silva Oliveira KC, Thomaz Araújo TM, Inagaki Albuquerque C, Alcantara Barata G, Oliveira Gigek C, Ferreira Leal M, et al. Role of miRNAs and their potential to be useful as diagnostic and prognostic biomarkers in gastric cancer. World J Gastroenterol. 2016;22(35):7951–62.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev. 2008;9(1):47–59.

    Article  CAS  Google Scholar 

  46. Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol. 2012;157(4):510–4.

    Article  CAS  PubMed  Google Scholar 

  47. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le T-B, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nat Publ Gr. 2016;538(7626):477–82.

    Google Scholar 

  48. Lennartsson J, Blume-Jensen P, Hermanson M, Pontén E, Carlberg M, Rönnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene. 1999;18(40):5546–53.

    Article  CAS  PubMed  Google Scholar 

  49. Shabnam B, Padmavathi G, Banik K, Girisa S, Monisha J, Sethi G, et al. Sorcin a potential molecular target for cancer therapy. Transl Oncol. 2018;11(6):1379–89. https://doi.org/10.1016/j.tranon.2018.08.015.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14(5):381–95.

    CAS  PubMed  Google Scholar 

  51. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345–56.

    CAS  PubMed  Google Scholar 

  52. Bonati A, Carlo-Stella C, Lunghi P, Albertini R, Pinelli S, Migliaccio E, et al. Selective expression and constitutive phosphorylation of SHC proteins in the CD34+ fraction of chronic myelogenous leukemias. Cancer Res. 2000;60(3):728–32.

    CAS  PubMed  Google Scholar 

  53. Goss VL, Lee KA, Moritz A, Nardone J, Spek EJ, MacNeill J, et al. A common phosphotyrosine signature for the Bcr-Abl kinase. Blood. 2006;107(12):4888–977.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Shih H-J, Chen H-H, Chen Y-A, Wu M-H, Liou G-G, Chang W-W, et al. Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity. Oncotarget. 2012;3(11):1401–15.

    PubMed  PubMed Central  Google Scholar 

  55. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25(3):463–72.

    CAS  PubMed  Google Scholar 

  56. Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, et al. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. Biochem Biophys Res Commun. 2014;448(4):430–6.

    CAS  PubMed  Google Scholar 

  57. Sugawara I, Mizumoto K, Ohkochi E, Hamada H, Tsuruo T, Mori S. Immunocytochemical identification and localization of the Mr 22,000 calcium-binding protein (Sorcin) in an adriamycin-resistant myelogenous leukemia cell line. Japanese J Cancer Res. 1989;80(5):469–74.

    CAS  Google Scholar 

  58. Parekh HK, Deng HB, Choudhary K, Houser SR, Simpkins H. Overexpression of sorcin, a calcium-binding protein, induces a low level of paclitaxel resistance in human ovarian and breast cancer cells. Biochem Pharmacol. 2002;63(6):1149–58.

    CAS  PubMed  Google Scholar 

  59. Zhou Y, Xu Y, Tan Y, Qi J, Xiao Y, Yang C, et al. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells. Leuk Res. 2006;30(4):469–76.

    Article  CAS  PubMed  Google Scholar 

  60. Tan Y, Li G, Zhao C, Wang J, Zhao H, Xue Y, et al. Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res. 2003;27(2):125–31.

    CAS  PubMed  Google Scholar 

  61. Tuo H, Shu F, She S, Yang M, Zou XQ, Huang J, et al. Sorcin induces gastric cancer cell migration and invasion contributing to STAT3 activation. Oncotarget. 2017;8(61):104258–71.

    PubMed  PubMed Central  Google Scholar 

  62. Gupta K, Sirohi VK, Kumari S, Shukla V, Manohar M, Popli P, et al. Sorcin is involved during embryo implantation via activating VEGF/PI3K/Akt pathway in mice. J Mol Endocrinol. 2018;60(2):119–32.

    CAS  PubMed  Google Scholar 

  63. Li G, Tan Y, Yang C, Zhao C, Zhao H, Wang J, et al. Expression and clinical implications of the soluble drug resistance-related calcium-binding protein (sorcin) gene in leukemia patients. Zhonghua Xue Ye Xue Za Zhi. 2002;23(6):293–6.

    PubMed  Google Scholar 

  64. Qi J, Liu N, Zhou Y, Tan Y, Cheng Y, Yang C, et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun. 2006;349(1):303–9.

    CAS  PubMed  Google Scholar 

  65. Haenisch S, Laechelt S, Bruckmueller H, Werk A, Noack A, Bruhn O, et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by MicroRNA-379. Mol Pharmacol. 2011;80(2):314–20.

    CAS  PubMed  Google Scholar 

  66. Campos-Melo D, Droppelmann CA, Volkening K, Strong MJ. Comprehensive luciferase-based reporter gene assay reveals previously masked up-regulatory effects of miRNAs. Int J Mol Sci. 2014;15(9):15592–60202.

    PubMed  PubMed Central  Google Scholar 

  67. Geng J, Liu Y, Jin Y, Tai J, Zhang J, Xiao X, et al. MicroRNA-365a-3p promotes tumor growth and metastasis in laryngeal squamous cell carcinoma. Oncol Rep. 2016;35(4):2017–26.

    CAS  PubMed  Google Scholar 

  68. Gastaldi C, Bertero T, Xu N, Bourget-Ponzio I, Lebrigand K, Fourre S, et al. miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma. Carcinogenesis. 2014;35(5):1110–20.

    CAS  PubMed  Google Scholar 

  69. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Falcão RP, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Brazilian J Med Biol Res. 2007;40(11):1435–40.

    CAS  Google Scholar 

  70. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.

    Article  CAS  PubMed  Google Scholar 

  71. Litwińska Z, Machaliński B. miRNAs in chronic myeloid leukemia: small molecules, essential function. Leuk Lymphoma. 2017;58(6):1297–305. https://doi.org/10.1080/10428194.2016.1243676.

    Article  CAS  PubMed  Google Scholar 

  72. Kok MGM, de Ronde MWJ, Moerland PD, Ruijter JM, Creemers EE, Pinto-Sietsma SJ. Small sample sizes in high-throughput miRNA screens: a common pitfall for the identification of miRNA biomarkers. Biomol Detect Quantif. 2017;2018(15):1–5.

    Google Scholar 

  73. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Alves R, Gonçalves AC, Jorge J, Marques G, Luís D, Ribeiro AB, et al. MicroRNA signature refine response prediction in CML. Sci Rep. 2019;9(1):9666.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Wan J, Ling X, Peng B, Ding G. miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway. Oncol Rep. 2018;40(1):272–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Xu W, Wang W. MicroRNA-142-5p modulates breast cancer cell proliferation and apoptosis by targeting phosphatase and tensin homolog. Mol Med Rep. 2018;17(6):7529–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Zhu X, Lin Z, Du J, Zhou X, Yang L, Liu G. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia. Mol Cell Biochem. 2014;390(1–2):75–84.

    Article  CAS  PubMed  Google Scholar 

  78. Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014;6(252):121.

    Article  CAS  Google Scholar 

  79. Warfvinge R, Geironson L, Sommarin MNE, Lang S, Karlsson C, Roschupkina T, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017;129(17):2384–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Cloonan N. Re-thinking miRNA-mRNA interactions: Intertwining issues confound target discovery. BioEssays. 2015;37(4):379–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017;23(6):692–702.

    Article  CAS  PubMed  Google Scholar 

  82. Gordon MY, Marley SB, Apperley JF, Marin D, Kaeda J, Szydlo R, et al. Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons. Br J Haematol. 2003;122(3):424–9.

    Article  PubMed  Google Scholar 

  83. Zhang J, Jiang Y, Han X, Roy M, Liu W, Zhao X, et al. Differential expression profiles and functional analysis of plasma miRNAs associated with chronic myeloid leukemia phases. Futur Oncol. 2018;15(7):763–76.

    Article  CAS  Google Scholar 

  84. Holland RL. What makes a good biomarker? Adv Precis Med. 2016;1(1):4–11.

    Article  Google Scholar 

  85. Wong NK, Huang CL, Islam R, Yip SP. Long non-coding RNAs in hematological malignancies: translating basic techniques into diagnostic and therapeutic strategies. J Hematol Oncol. 2018;11(1):1–22.

    Article  CAS  Google Scholar 

  86. Xiao Y, Jiao C, Lin Y, Chen M, Zhang J, Wang J, et al. lncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells. DNA Cell Biol. 2016;36(1):18–25.

    Article  PubMed  CAS  Google Scholar 

  87. He B, Bai Y, Kang W, Zhang X, Jiang X. LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res. 2017;7(8):1704–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2(1):17023.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Flamant S, Ritchie W, Guilhot J, Holst J, Bonnet M-L, Chomel J-C, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95(8):1325–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Britta Schwarten, Irina Naujoks and Anna Jürgensen for their excellent technical assistance.

Funding

Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Medical Faculty of the University of Kiel, Kiel, Germany.

Author information

Author notes

  1. Theresa Klümper and Henrike Bruckmueller contributed equally to this work.

Authors and Affiliations

  1. Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany

    Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Oliver Bruhn & Ingolf Cascorbi

  2. Department of Medicine II, Haematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, 24105, Kiel, Germany

    Christiane Pott

Authors
  1. Theresa Klümper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henrike Bruckmueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Diewock
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meike Kaehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sierk Haenisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christiane Pott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Oliver Bruhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ingolf Cascorbi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

OB, IC, SH, CP conceptualized this study. CP provided patient material. HB, OB designed the experiments. TD, TK, MK, OB, HB performed the experiments. TK, MK, TD, HB, OB analyzed and interpreted the data. TK, HB prepared figures and tables. TK, HB, OB drafted the manuscript. TD, MK, SH, CP, IC reviewed and edited the manuscript. HB, OB, IC supervised the project. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Oliver Bruhn or Ingolf Cascorbi.

Ethics declarations

Ethics approval and consent to participate

The study was conducted according to the guidelines of Helsinki and was approved by the Ethics Committee of the Medical Faculty of Kiel University, Germany (reference number: D 426/03). Each patient gave his written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Table S1.

Vector constructs used in reporter gene assays for target gene evaluation of the selected miRNAs. Table S2. Selected target genes of miR-142-5p and miR-365a-3p, which were analyzed in reporter gene-assays including a summary of their relevance in CML. Table S3. Full terms of abbreviations. Figure S1. Reporter gene assays indicated no interaction between miR-142-5p and SHC4 3’-UTR. The SHC4 3’-UTR containing vector was co-transfection with pre-miR-142-5p and reporter gene activity were measured after 48 h. (A) The reporter gene assay resulted in no significant suppression of relative reporter gene activity. (B) Predicted interaction between miR-142-5p and SHC4 3’-UTR is shown here. All activities (n ≥ 12, median ± interquartile range) were normalized to activities of cells transfected with respective 3′-UTR target sequence vectors and pre-miR negative control. Activities are shown relative to empty control vector (c) identically transfected and normalized as 3′-UTR target sequence vectors, Mann-Whitney U-test.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klümper, T., Bruckmueller, H., Diewock, T. et al. Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance. Exp Hematol Oncol 9, 26 (2020). https://doi.org/10.1186/s40164-020-00183-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40164-020-00183-1

Keywords

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us